- Home
- TYGO vs AGEN Comparison
TYGO vs AGEN Comparison
Compare TYGO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- AGEN
- Stock Information
- Founded
- TYGO 2007
- AGEN 1994
- Country
- TYGO United States
- AGEN United States
- Employees
- TYGO N/A
- AGEN N/A
- Industry
- TYGO Semiconductors
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TYGO Technology
- AGEN Health Care
- Exchange
- TYGO Nasdaq
- AGEN Nasdaq
- Market Cap
- TYGO 97.2M
- AGEN 106.8M
- IPO Year
- TYGO N/A
- AGEN 2000
- Fundamental
- Price
- TYGO $1.49
- AGEN $4.87
- Analyst Decision
- TYGO Buy
- AGEN Buy
- Analyst Count
- TYGO 3
- AGEN 3
- Target Price
- TYGO $3.00
- AGEN $10.00
- AVG Volume (30 Days)
- TYGO 50.1K
- AGEN 411.8K
- Earning Date
- TYGO 11-05-2024
- AGEN 11-05-2024
- Dividend Yield
- TYGO N/A
- AGEN N/A
- EPS Growth
- TYGO N/A
- AGEN N/A
- EPS
- TYGO N/A
- AGEN N/A
- Revenue
- TYGO $48,852,000.00
- AGEN $159,630,000.00
- Revenue This Year
- TYGO N/A
- AGEN N/A
- Revenue Next Year
- TYGO $84.74
- AGEN $0.04
- P/E Ratio
- TYGO N/A
- AGEN N/A
- Revenue Growth
- TYGO N/A
- AGEN 60.67
- 52 Week Low
- TYGO $0.86
- AGEN $4.41
- 52 Week High
- TYGO $7.49
- AGEN $23.20
- Technical
- Relative Strength Index (RSI)
- TYGO 50.83
- AGEN 40.70
- Support Level
- TYGO $1.41
- AGEN $4.51
- Resistance Level
- TYGO $1.74
- AGEN $5.81
- Average True Range (ATR)
- TYGO 0.18
- AGEN 0.43
- MACD
- TYGO -0.01
- AGEN -0.04
- Stochastic Oscillator
- TYGO 32.49
- AGEN 17.82
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).